Lyra Therapeutics (LYRA) Operating Leases (2021 - 2025)
Historic Operating Leases for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $26.7 million.
- Lyra Therapeutics' Operating Leases fell 1476.96% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.7 million, marking a year-over-year decrease of 1476.96%. This contributed to the annual value of $30.3 million for FY2024, which is 4108.73% up from last year.
- According to the latest figures from Q3 2025, Lyra Therapeutics' Operating Leases is $26.7 million, which was down 1476.96% from $27.9 million recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Operating Leases registered a high of $33.4 million during Q1 2024, and its lowest value of $3000.0 during Q2 2022.
- For the 5-year period, Lyra Therapeutics' Operating Leases averaged around $13.4 million, with its median value being $3.0 million (2021).
- In the last 5 years, Lyra Therapeutics' Operating Leases crashed by 9967.71% in 2022 and then skyrocketed by 16280000.0% in 2023.
- Over the past 5 years, Lyra Therapeutics' Operating Leases (Quarter) stood at $379000.0 in 2021, then soared by 75.99% to $667000.0 in 2022, then surged by 3115.44% to $21.4 million in 2023, then soared by 41.09% to $30.3 million in 2024, then dropped by 11.78% to $26.7 million in 2025.
- Its Operating Leases stands at $26.7 million for Q3 2025, versus $27.9 million for Q2 2025 and $29.1 million for Q1 2025.